DOI: https://doi.org/10.22263/2312-4156.2026.3.88
A.A. Nidelko
Assessment of nasal breathing dynamics after cell therapy in patients with chronic polypous rhinosinusitis: results of a pilot study
Republican Scientific and Practical Center of Otorhinolaryngology, Minsk, Republic of Belarus
Vestnik VGMU. 2026;25(3):88-93.
Abstract.
Objectives. To assess nasal breathing using anterior active rhinomanometry (AAR) in patients with chronic rhinosinusitis with nasal polyps (CRSwNP) after the use of a biomedical cell product (BCP) based on olfactory ensheathing mesenchymal stem cells (OE-MSCs) and without its use.
Material and methods. The study included 50 patients with CRSwNP: main group No. 1 (MG1, n=12) – administration of BCP 2– during 5 months after surgery; main group No. 2 (MG2, n=13) – administration of BCP in the perioperative period; control group (CG, n=25) – surgical treatment only. All patients underwent functional endoscopic sinus surgery followed by treatment according to clinical protocols. The BCP based on OE-MSCs was injected into the nasal mucosa once (in MG2, one patient received it twice). AAR was performed before surgery, at 3 and 12 months.
Results. 3 months after surgery, there were no differences between the groups (p>0.05). After 12 months, in MG1 and MG2, the volumetric flow rate was significantly higher and resistance was significantly lower than in the CG (p<0.05). The median volumetric flow rate after one year was: MG1 – 359.88 [343.25; 370.81] cm³/s, MG2 – 353.00 [327.25; 360.00] cm³/s, CG – 315.5 [287.25; 341.75] cm³/s; resistance: MG1 – 0.42 [0.41; 0.45] Pa/cm³/s, MG2 – 0.43 [0.42; 0.47] Pa/cm³/s, CG – 0.48 [0.44; 0.56] Pa/cm³/s.
Conclusions. According to the results of this study, patients who received cell therapy using BCP based on OE-MSCs had better nasal breathing according to objective AAR 1 year after surgery compared to the control group.
Keywords: chronic rhinosinusitis with nasal polyps, mesenchymal stem cells, olfactory mucosa, cell therapy, active anterior rhinomanometry, nasal breathing, biomedical cell product.
Funding sources. The work was carried out within the framework of the clinical research program under activity 25 (27) “Develop a biomedical cell product based on olfactory mucosa mesenchymal stem cells with improved immunosuppressive and anti-inflammatory properties” of subprogram 1 “Innovative biotechnologies” 2021-2023, state program “High-tech technologies and engineering” for 2021-2025.
Acknowledgment. Institute of Biophysics and Cell Engineering of the National Academy of Sciences of Belarus (for the production of the biomedical cell product), as well as the reviewers for reviewing the article.
References
1. Savietto E, Marioni G, Maculan P, Pettorelli A, Scarpa B, Simoni E, et al. Effectiveness of micronized nasal irrigations with hyaluronic acid/isotonic saline solution in non-polipoid chronic rhinosinusitis: a prospective, randomized, double-blind, controlled study. American Journal of Otolaryngology. 2020 Jul-Aug;41(4):102502. doi: http://dx.doi.org/10.1016/j.amjoto.2020.102502
2. Klimek L, Förster-Ruhrmann U, Olze H, Beule AG, Chaker AM, Hagemann J, et al. Monitoring mepolizumab treatment in chronic rhinosinusitis with nasal polyps (CRSwNP): discontinue, change, continue therapy? Allergologie Select. 2024 Mar;8:26-39. doi: http://dx.doi.org/10.5414/ALX02460E
3. Giombi F, Pace GM, Mari G, Cerasuolo M, Sandri G, Cerri L, et al. Assessing nasal obstruction improvement in dupilumab-treated patients with active anterior rhinomanometry: a preliminary study. Ear, Nose, and Throat Journal. 2025 Jun:1455613251350508. doi: http://dx.doi.org/10.1177/01455613251350508
4. Araújo-Martins J, Brás-Geraldes C, Neuparth N. The potential role of peak nasal inspiratory flow to evaluate active sinonasal inflammation and disease severity. Scientific Reports. 2020 Jul:1(1):12674. doi: http://dx.doi.org/10.1038/s41598-020-69693-6
5. Nidelko AA. Features of the rhinocytogram in cell therapy in patients with chronic polyposis rhinosinusite. Evraziiskaya Otorinolaringologiya i Audiologiya. 2025;15(3):292-304. (In Russ.). doi: http://dx.doi.org/10.34883/PI.2025.15.3.027
6. Nidelko AA, Shulepova EA. Evaluation of the efficacy of cell therapy in patients with chronic polyposis rhinosinusite by nasal endoscopy. Meditsinskie Novosti. 2026;(4):64-67. (In Russ.).
7. Nidelko AA. Quality of life assessment for SNOT-22 in cell therapy in patients with chronic polypose rhinosinusite. Evraziiskaya Otorinolaringologiya i Audiologiya. 2025;1(4):495-505. (In Russ.). doi: http://dx.doi.org/10.34883/PI.2025.15.4.033
8. Nidelko AA, Ryabtseva SN, Shulepova EA. Evaluation of the effectiveness of use of mesenchymal olfactory stem cells in the treatment of chronic polyposis rhinosinusitis based on data from a morphological analysis of the nasal mucosa. Otorinolaringlogiya Vostochnaya Evropa. 2024;14(3 elektron pril):53-56. URL: https://recipe.by/wp-content/uploads/2024/11/Tezisy-yelektronnyy-sbornik-po-otorino_05_11_2024_N3.pdf [Accessed 15th June 2026]. (In Russ.).
9. Li L, Liu Z, Zhang C, Long Y, Yang T. Rat nasal mucosa-derived ectodermal mesenchymal stem cells: A new therapeutic option for chronic rhinosinusitis. Immunity, Inflammation and Disease. 2024 Jul;12(7):e1337. doi: http://dx.doi.org/10.1002/iid3.1337
10. Eremenko YuE, Shulepova EA, Nidelko AA. Gurbo VE, Antonevich NG, Goncharov AE. Evaluation of the safety of use of mesenchymal olfactory stem cells for chronic polyposis rhinocytosis therapy. Lechashchii Vrach. 2025;28(10):11-17. (In Russ.). doi: http://dx.doi.org/10.51793/OS.2025.28.10.001
Submitted 05.03.2026
Accepted 19.06.2026
Information about authors:
Anastasiya A. Nidelko – otolaryngologist of the Otolaryngology Department for Children of the Hospital, research fellow, postgraduate student, Republican Scientific and Practical Center of Otorhinolaryngology, e-mail: Этот адрес электронной почты защищён от спам-ботов. У вас должен быть включен JavaScript для просмотра..
